Value
5.2/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.9 |
| Fwd P/E | 2.7 |
| PEG | 4.3 |
| Analyst target | 3.0 |
- ▸Forward P/E: 41.3x
- ▸PEG: 2.15
HIMS · Why this verdict
Why Hims & Hers Health (HIMS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality falls below the minimum acceptable floor with no identifiable competitive moat, a Rule of 40 score of just 11 (well below the 40 threshold), and operating and net margins at negligible levels on a GAAP basis. Quality breakdown | Rule of 40 rises above 25 within 12 months as revenue growth accelerates and early operating leverage materializes, moving quality toward an acceptable range. | →Stable |
| CounterThe company is FCF-positive despite GAAP losses, with a 7% FCF margin and a Piotroski F-Score of 8/9, suggesting the underlying cash business may be healthier than GAAP metrics and the Rule of 40 imply. | ||
Short interest at 33% of the float, paired with implied volatility at 102%, indicates a significant concentration of sellers positioned for further decline and an options market pricing substantial uncertainty about the path forward. Risk breakdown | Short interest falls below 20% as bearish catalysts fail to materialize or a squeeze produces a meaningful recovery, forcing covering at scale. | →Stable |
| CounterElevated short interest can become a powerful reverse-catalyst; if the company delivers unexpectedly strong results, forced covering from the 33% short base could amplify upside well beyond what fundamentals alone would support. | ||
The stock currently trades above the resistance-based price target, producing a negative expected return from current entry levels and an unfavorable risk/reward ratio where the potential downside materially outweighs any remaining upside. Price targets | Price pulls back below the $29.67 resistance target and analyst coverage revisions lift the consensus target above $38, restoring constructive entry geometry. | →Stable |
| CounterIf the company delivers a positive fundamental catalyst — an FDA-favorable development or a material earnings beat — the resistance target could be revised sharply higher, resetting the geometry favorably from a new baseline. | ||
The stock is in a confirmed downtrend with the 200-day moving average declining at over 10% per month — a steep deterioration that historically requires a meaningful fundamental catalyst to reverse and that makes near-term technical recovery challenging. Momentum breakdown | Price reclaims and holds above the 200-day moving average for 4 consecutive weeks and the moving average slope turns positive, confirming a genuine trend reversal. | →Stable |
| CounterRSI at 69 and an improving MACD suggest near-term momentum is recovering; a stock can begin a genuine fundamental turnaround while still below the 200-day average if buyers absorb supply efficiently at current levels. | ||
Business quality falls below the minimum acceptable floor with no identifiable competitive moat, a Rule of 40 score of just 11 (well below the 40 threshold), and operating and net margins at negligible levels on a GAAP basis.
→StableQuality breakdown
- Expectation
- Rule of 40 rises above 25 within 12 months as revenue growth accelerates and early operating leverage materializes, moving quality toward an acceptable range.
CounterThe company is FCF-positive despite GAAP losses, with a 7% FCF margin and a Piotroski F-Score of 8/9, suggesting the underlying cash business may be healthier than GAAP metrics and the Rule of 40 imply.
Short interest at 33% of the float, paired with implied volatility at 102%, indicates a significant concentration of sellers positioned for further decline and an options market pricing substantial uncertainty about the path forward.
→StableRisk breakdown
- Expectation
- Short interest falls below 20% as bearish catalysts fail to materialize or a squeeze produces a meaningful recovery, forcing covering at scale.
CounterElevated short interest can become a powerful reverse-catalyst; if the company delivers unexpectedly strong results, forced covering from the 33% short base could amplify upside well beyond what fundamentals alone would support.
The stock currently trades above the resistance-based price target, producing a negative expected return from current entry levels and an unfavorable risk/reward ratio where the potential downside materially outweighs any remaining upside.
→StablePrice targets
- Expectation
- Price pulls back below the $29.67 resistance target and analyst coverage revisions lift the consensus target above $38, restoring constructive entry geometry.
CounterIf the company delivers a positive fundamental catalyst — an FDA-favorable development or a material earnings beat — the resistance target could be revised sharply higher, resetting the geometry favorably from a new baseline.
The stock is in a confirmed downtrend with the 200-day moving average declining at over 10% per month — a steep deterioration that historically requires a meaningful fundamental catalyst to reverse and that makes near-term technical recovery challenging.
→StableMomentum breakdown
- Expectation
- Price reclaims and holds above the 200-day moving average for 4 consecutive weeks and the moving average slope turns positive, confirming a genuine trend reversal.
CounterRSI at 69 and an improving MACD suggest near-term momentum is recovering; a stock can begin a genuine fundamental turnaround while still below the 200-day average if buyers absorb supply efficiently at current levels.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Hims & Hers screens below the minimum quality threshold, trades above its resistance-based price target with negative expected return from current levels, and carries 33% short interest in a confirmed downtrend; the risk/reward geometry is unfavorable, with downside exceeding upside, and the balance of evidence supports reducing rather than building the position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.4 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.1 |
| FCF quality | 4.5 |
| Moat | 4.6 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸FCF-positive despite GAAP loss (FCF margin 7%, FCF yield 2.0%)
- ▸No competitive moat
- ▸Rule of 40: 11 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
3.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 71)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.5 |
| Analyst rating | 5.0 |
| Price target | 1.9 |
- ▸Below analyst target
Insider
4.2/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.8 |
| holder change | 5.2 |
- ▸Modest insider selling — $2,794,379 (0.033% of mkt cap)
Peer rank
2.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.3 |
| quality rank | 3.9 |
| growth rank | 4.2 |
Technical
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.6 |
| support resistance | 1.3 |
| 52w position | 0.6 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.1 |
| days to cover | 7.3 |
| volatility | 0.0 |
| put call | 7.9 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 2.2 |
| debt equity | 2.5 |
| news risk | 5.0 |
- ▸High short interest justified: 34%
- ▸High IV: 107%
- ▸Above max pain $15
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-2.3=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=6.5>=5.0 recovering
Reward-to-Risk
-2.27
Upside
-34.0%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 71
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -47% (>40% off 52w high)
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 6.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-2.3=NEGATIVE.
The strongest dimensions are Momentum at 6.5, Value at 5.2, and Catalyst at 4.9; the weakest are Technical at 1.2, Peer rank at 2.8, and Risk (lower is worse) at 3.1. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -2.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum No Moat
Trip ifRule of 40 metric rises above 25 for 2 consecutive quarters, indicating quality is recovering toward an acceptable baseline.
- P2Price Above Target Negative Geometry
Trip ifAnalyst consensus price target rises above $38, restoring more than 10% upside headroom from current levels.
- P3Extreme Short Interest Downside Signal
Trip ifShort interest falls below 15% for 2 consecutive months, indicating the bearish thesis is being abandoned at scale.
- P4Confirmed Downtrend Steep Slope
Trip ifPrice holds above the 200-day moving average for 4 consecutive weeks while the moving average slope turns positive.